Pacira Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PCRX)

$45.80 0.45 (0.99 %)
(As of 12/14/2017 10:10 AM ET)
Previous Close$45.35
Today's Range$44.95 - $46.19
52-Week Range$29.81 - $58.95
Volume412,600 shs
Average Volume831,126 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.2

About Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Debt-to-Equity Ratio1.03%
Current Ratio6.99%
Quick Ratio6.24%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$276.37 million
Price / Sales6.72
Cash Flow$0.31 per share
Price / Cash148.63
Book Value$5.85 per share
Price / Book7.83

Profitability

Trailing EPS($1.31)
Net Income$-37,940,000.00
Net Margins-18.25%
Return on Equity-13.77%
Return on Assets-6.34%

Miscellaneous

Employees503
Outstanding Shares40,570,000

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) issued its quarterly earnings results on Wednesday, November, 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.15. The firm earned $67.30 million during the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm's quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the company posted $0.20 EPS. View Pacira Pharmaceuticals' Earnings History.

When will Pacira Pharmaceuticals make its next earnings announcement?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Pacira Pharmaceuticals.

Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2017?

17 Wall Street analysts have issued 1-year price targets for Pacira Pharmaceuticals' shares. Their predictions range from $27.00 to $80.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $49.38 in the next year. View Analyst Ratings for Pacira Pharmaceuticals.

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt." (10/9/2017)
  • 2. Cowen Inc analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
  • 3. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:

  • David M. Stack, Chairman of the Board, Chief Executive Officer (Age 66)
  • Charles A. Reinhart III, Chief Financial Officer (Age 56)
  • Scott N. Braunstein M.D., Chief Operating Officer (Age 53)
  • James B. Jones M.D., Senior Vice President, Chief Medical Officer (Age 52)
  • Kristen Marie Williams, Chief Administrative Officer, General Counsel, Secretary (Age 43)
  • Richard Scranton M.D., Chief Scientific Officer
  • Robert J. Weiland, Chief Commercial Officer (Age 57)
  • Mark Froimson, Director
  • Gary Pace Ph.D., Director (Age 69)
  • Laura A. Brege, Independent Director (Age 59)

Who owns Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Westfield Capital Management Co. LP (3.17%), Macquarie Group Ltd. (2.86%), Stephens Investment Management Group LLC (2.50%), Schroder Investment Management Group (2.35%), Alyeska Investment Group L.P. (1.57%) and Elk Creek Partners LLC (1.51%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Alyeska Investment Group L.P., Russell Investments Group Ltd., Oak Ridge Investments LLC, Ameriprise Financial Inc., Axiom International Investors LLC DE, Sei Investments Co. and California State Teachers Retirement System. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Equity Management, Stonepine Capital Management LLC, Epoch Investment Partners Inc., Mutual of America Capital Management LLC, Rice Hall James & Associates LLC, Westfield Capital Management Co. LP, Stephens Investment Management Group LLC and Macquarie Group Ltd.. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include James B Jones, John P Phd Longenecker, Mark A Kronenfeld, Mark Froimson and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy Pacira Pharmaceuticals stock?

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $45.80.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.84 billion and generates $276.37 million in revenue each year. The company earns $-37,940,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Pacira Pharmaceuticals employs 503 workers across the globe.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


MarketBeat Community Rating for Pacira Pharmaceuticals (PCRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  533 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  810
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacira Pharmaceuticals (NASDAQ:PCRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.392.442.532.59
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.38$50.31$53.42$63.87
Price Target Upside: 7.12% upside25.53% upside43.79% upside35.31% upside

Pacira Pharmaceuticals (NASDAQ:PCRX) Consensus Price Target History

Price Target History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017Canaccord GenuitySet Price TargetHold$42.00LowView Rating Details
11/29/2017MizuhoDowngradeBuy -> Neutral$53.00 -> $44.00MediumView Rating Details
11/20/2017WedbushReiterated RatingBuy$80.00N/AView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetSell$27.00N/AView Rating Details
11/9/2017OppenheimerReiterated RatingHoldN/AView Rating Details
11/9/2017HC WainwrightReiterated RatingBuy -> Buy$52.00N/AView Rating Details
11/9/2017Jefferies GroupLower Price TargetBuy$52.00N/AView Rating Details
11/8/2017BMO Capital MarketsBoost Price TargetMarket Perform$38.00 -> $39.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$55.00N/AView Rating Details
10/19/2017Needham & Company LLCLower Price TargetBuy -> Buy$55.00 -> $52.00N/AView Rating Details
10/13/2017Royal Bank of CanadaReiterated RatingBuy$54.00N/AView Rating Details
10/4/2017Bank of AmericaLower Price TargetBuy$46.00 -> $45.00LowView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$41.00MediumView Rating Details
9/7/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
8/2/2017CowenReiterated RatingHoldMediumView Rating Details
3/21/2017BarclaysReiterated RatingOverweight -> Overweight$54.00 -> $59.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformHighView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00N/AView Rating Details
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings History and Estimates Chart

Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ PCRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$0.11N/AView Earnings Details
11/8/2017Q3 2017($0.04)$0.11$68.99 million$67.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.11)$73.37 million$70.90 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.23)($0.19)$70.30 million$69.30 millionViewListenView Earnings Details
3/1/2017Q416$0.01$0.09$73.08 million$72.90 millionViewListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.25)($0.25)($0.25)
Q3 20172($0.29)($0.10)($0.20)
Q4 20173($0.31)$0.08($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/20/2017James B. JonesSVPSell850$41.11$34,943.50View SEC Filing  
11/17/2017Kristen Marie WilliamsCAOSell10,000$40.00$400,000.00View SEC Filing  
11/15/2017David M StackCEOSell58,885$38.34$2,257,650.90View SEC Filing  
11/10/2017Mark A KronenfeldDirectorBuy1,000$41.60$41,600.00View SEC Filing  
8/22/2017Paul J HastingsDirectorSell1,044$36.15$37,740.60View SEC Filing  
8/15/2017David M StackCEOSell28,885$36.37$1,050,547.45View SEC Filing  
8/15/2017Kristen Marie WilliamsCAOSell3,461$36.75$127,191.75View SEC Filing  
8/8/2017Mark FroimsonDirectorBuy100$37.13$3,713.00View SEC Filing  
6/5/2017David M StackCEOSell4,311$43.32$186,752.52View SEC Filing  
6/5/2017James S ScibettaPresidentSell1,966$43.32$85,167.12View SEC Filing  
6/5/2017Kristen Marie WilliamsCAOSell1,877$43.32$81,311.64View SEC Filing  
6/5/2017Lauren Bullaro RikerVPSell601$43.32$26,035.32View SEC Filing  
6/5/2017Scott BraunsteinSVPSell768$43.32$33,269.76View SEC Filing  
5/15/2017James S ScibettaPresidentSell20,000$51.20$1,024,000.00View SEC Filing  
5/15/2017Kristen Marie WilliamsCAOSell21,041$50.86$1,070,145.26View SEC Filing  
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.00View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacira Pharmaceuticals (NASDAQ PCRX) News Headlines

Source:
DateHeadline
Stocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS RatingStocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS Rating
finance.yahoo.com - December 13 at 10:44 AM
 Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Quarterly Sales of $77.59 Million Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Quarterly Sales of $77.59 Million
www.americanbankingnews.com - December 12 at 8:18 AM
Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue?Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue?
finance.yahoo.com - December 11 at 11:03 AM
 Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) to Announce $0.12 Earnings Per Share Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) to Announce $0.12 Earnings Per Share
www.americanbankingnews.com - December 10 at 11:20 AM
Pacira Pharmaceuticals Sees RS Rating Climb To 75Pacira Pharmaceuticals Sees RS Rating Climb To 75
finance.yahoo.com - December 9 at 10:22 AM
Pacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer - MarketWatchPacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer - MarketWatch
www.marketwatch.com - December 8 at 10:21 AM
Pacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific Officer - StreetInsider.comPacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific Officer - StreetInsider.com
www.streetinsider.com - December 7 at 4:51 PM
Pacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific OfficerPacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific Officer
www.streetinsider.com - December 7 at 10:45 AM
Pacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officerPacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer
finance.yahoo.com - December 7 at 10:45 AM
Notable Two Hundred Day Moving Average Cross - PCRXNotable Two Hundred Day Moving Average Cross - PCRX
www.nasdaq.com - December 6 at 4:36 PM
Contrasting Dr. Reddys Laboratories (RDY) and Pacira Pharmaceuticals (PCRX)Contrasting Dr. Reddy's Laboratories (RDY) and Pacira Pharmaceuticals (PCRX)
www.americanbankingnews.com - December 5 at 1:10 AM
Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc ...Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc ...
www.prnewswire.com - November 30 at 4:33 PM
Pacira Pharmaceuticals (PCRX) PT Set at $42.00 by Canaccord GenuityPacira Pharmaceuticals (PCRX) PT Set at $42.00 by Canaccord Genuity
www.americanbankingnews.com - November 30 at 12:00 PM
Pacira Pharmaceuticals, Inc. (PCRX) Given Average Rating of "Hold" by BrokeragesPacira Pharmaceuticals, Inc. (PCRX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 1:52 AM
Pacira Pharmaceuticals (PCRX) Stock Rating Lowered by MizuhoPacira Pharmaceuticals (PCRX) Stock Rating Lowered by Mizuho
www.americanbankingnews.com - November 29 at 8:54 PM
Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid UseCancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid Use
finance.yahoo.com - November 29 at 10:26 AM
 Brokerages Expect Pacira Pharmaceuticals, Inc. (PCRX) Will Post Quarterly Sales of $77.59 Million Brokerages Expect Pacira Pharmaceuticals, Inc. (PCRX) Will Post Quarterly Sales of $77.59 Million
www.americanbankingnews.com - November 24 at 8:24 AM
FY2017 EPS Estimates for Pacira Pharmaceuticals, Inc. (PCRX) Boosted by WedbushFY2017 EPS Estimates for Pacira Pharmaceuticals, Inc. (PCRX) Boosted by Wedbush
www.americanbankingnews.com - November 23 at 7:58 AM
James B. Jones Sells 850 Shares of Pacira Pharmaceuticals, Inc. (PCRX) StockJames B. Jones Sells 850 Shares of Pacira Pharmaceuticals, Inc. (PCRX) Stock
www.americanbankingnews.com - November 20 at 8:25 PM
Kristen Marie Williams Sells 10,000 Shares of Pacira Pharmaceuticals, Inc. (PCRX) StockKristen Marie Williams Sells 10,000 Shares of Pacira Pharmaceuticals, Inc. (PCRX) Stock
www.americanbankingnews.com - November 20 at 7:38 PM
Pacira Pharmaceuticals, Inc. (PCRX) CEO Sells $2,257,650.90 in StockPacira Pharmaceuticals, Inc. (PCRX) CEO Sells $2,257,650.90 in Stock
www.americanbankingnews.com - November 17 at 7:46 PM
Pacira Pharmaceuticals, Inc. (PCRX) Given a $27.00 Price Target by Janney Montgomery Scott AnalystsPacira Pharmaceuticals, Inc. (PCRX) Given a $27.00 Price Target by Janney Montgomery Scott Analysts
www.americanbankingnews.com - November 16 at 10:38 AM
Pacira Pharma (PCRX) Reports FDA Advisory Committee Meeting to Review sNDA for EXPARELPacira Pharma (PCRX) Reports FDA Advisory Committee Meeting to Review sNDA for EXPAREL
www.streetinsider.com - November 15 at 7:19 AM
This Biotech Is Feeling The Pain After FDA Sets Panel On AnestheticThis Biotech Is Feeling The Pain After FDA Sets Panel On Anesthetic
finance.yahoo.com - November 15 at 7:19 AM
Pacira Pharmaceuticals, Inc. (PCRX) Director Buys $41,600.00 in StockPacira Pharmaceuticals, Inc. (PCRX) Director Buys $41,600.00 in Stock
www.americanbankingnews.com - November 13 at 10:50 PM
Critical Survey: Pacira Pharmaceuticals (PCRX) versus Apricus Biosciences (APRI)Critical Survey: Pacira Pharmaceuticals (PCRX) versus Apricus Biosciences (APRI)
www.americanbankingnews.com - November 13 at 9:18 PM
Pacira Pharmaceuticals, Inc. (PCRX) Price Target Raised to $38.00Pacira Pharmaceuticals, Inc. (PCRX) Price Target Raised to $38.00
www.americanbankingnews.com - November 9 at 8:54 PM
Pacira Pharmaceuticals (PCRX) "Hold" Rating Reiterated at Oppenheimer Holdings, Inc.Pacira Pharmaceuticals' (PCRX) "Hold" Rating Reiterated at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 9 at 1:54 PM
Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; Higher Gross Margin and Lower R&D - StreetInsider.comPacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D' - StreetInsider.com
www.streetinsider.com - November 9 at 11:08 AM
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates - NasdaqPacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates - Nasdaq
www.nasdaq.com - November 9 at 11:08 AM
Pacira Pharmaceuticals (PCRX) Q3 2017 Results - Earnings Call Transcript - Seeking AlphaPacira Pharmaceuticals (PCRX) Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 11:08 AM
Edited Transcript of PCRX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of PCRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 11:07 AM
Pacira Pharmaceuticals, Inc. (PCRX) Issues Quarterly  Earnings ResultsPacira Pharmaceuticals, Inc. (PCRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 11:54 PM
Pacira Pharmaceuticals, Inc. (PCRX) Stock Rating Reaffirmed by BMO Capital MarketsPacira Pharmaceuticals, Inc. (PCRX) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - November 8 at 11:40 PM
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : November 6, 2017Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : November 6, 2017
finance.yahoo.com - November 7 at 8:35 AM
ETFs with exposure to Pacira Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to Pacira Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 8:35 AM
Pacira Pharmaceuticals, Inc. (PCRX) Receives Consensus Rating of "Hold" from BrokeragesPacira Pharmaceuticals, Inc. (PCRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 1:32 AM
Pacira Pharmaceuticals, Inc. (PCRX) Expected to Announce Earnings of -$0.04 Per SharePacira Pharmaceuticals, Inc. (PCRX) Expected to Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - November 2 at 9:36 PM
Pacira Pharmaceuticals, Inc. (PCRX) Set to Announce Quarterly Earnings on WednesdayPacira Pharmaceuticals, Inc. (PCRX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 9:46 AM
Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference CallPacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call
finance.yahoo.com - October 31 at 7:39 AM
Pacira Pharmaceuticals, Inc. (PCRX) Cut to Hold at Canaccord GenuityPacira Pharmaceuticals, Inc. (PCRX) Cut to Hold at Canaccord Genuity
www.americanbankingnews.com - October 30 at 6:16 AM
Jefferies Group Weighs in on Pacira Pharmaceuticals, Inc.s Q3 2017 Earnings (PCRX)Jefferies Group Weighs in on Pacira Pharmaceuticals, Inc.'s Q3 2017 Earnings (PCRX)
www.americanbankingnews.com - October 30 at 1:22 AM
Janney Montgomery Scott Lowers Pacira Pharmaceuticals Inc (PCRX) to SellJanney Montgomery Scott Lowers Pacira Pharmaceuticals Inc (PCRX) to Sell
www.americanbankingnews.com - October 26 at 7:38 AM
Pacira Pharma (PCRX) to Invest $25M in TELA Bio - StreetInsider.comPacira Pharma (PCRX) to Invest $25M in TELA Bio - StreetInsider.com
www.streetinsider.com - October 25 at 8:55 AM
ETFs with exposure to Pacira Pharmaceuticals, Inc. : October 24, 2017ETFs with exposure to Pacira Pharmaceuticals, Inc. : October 24, 2017
finance.yahoo.com - October 25 at 8:55 AM
Pacira Pharmaceuticals and TELA Bio Announce Equity AgreementPacira Pharmaceuticals and TELA Bio Announce Equity Agreement
finance.yahoo.com - October 25 at 8:55 AM
Pacira Pharmaceuticals, Inc. (PCRX) to Release Quarterly Earnings on TuesdayPacira Pharmaceuticals, Inc. (PCRX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 6:40 AM
Featured Company News - Pacira Announces FDA Acceptance of sNDA for EXPARELFeatured Company News - Pacira Announces FDA Acceptance of sNDA for EXPAREL
finance.yahoo.com - October 21 at 8:03 AM
Pacira Pharma (PCRX) Says FDA Accepted sNDA for EXPAREL as ... - StreetInsider.comPacira Pharma (PCRX) Says FDA Accepted sNDA for EXPAREL as ... - StreetInsider.com
www.streetinsider.com - October 20 at 7:19 AM
Pacira Pharmaceuticals, Inc. (PCRX) PT Lowered to $52.00Pacira Pharmaceuticals, Inc. (PCRX) PT Lowered to $52.00
www.americanbankingnews.com - October 19 at 8:19 AM

SEC Filings

Pacira Pharmaceuticals (NASDAQ:PCRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacira Pharmaceuticals (NASDAQ:PCRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacira Pharmaceuticals (NASDAQ PCRX) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.